Objective:

To review the limitations of current levothyroxine therapy, examine the clinical evidence for its underperformance, and propose an Intelligent Medicine Bot (IMB) for improved thyroid hormone replacement.

Approach:

• Clinical Evidence Review: Examines the clinical evidence for why fixed-dose L-T4 therapy underperforms and its multi-organ consequences.
• Technology Survey: Surveys maturing technologies such as thyroid hormone biosensors, machine learning dosing models, and miniaturized drug delivery devices, assessing their readiness levels.
• Proposed Integration: Proposes the integration of these technologies into a closed-loop Intelligent Medicine Bot (IMB) and outlines the development pathway toward clinical translation, identifying key controversies and research gaps.

Key Findings:

• Only about 34% of thyroidectomized patients achieve target euthyroidism post-operatively.
• Levothyroxine therapy is characterized by significant variability in absorption and individual response.
• Current fixed-dose L-T4 therapy fails to adapt to physiological changes in patients, leading to consequences such as cardiac arrhythmias, bone mineral loss, cognitive fog, metabolic disruption, and impaired fertility.

Interpretation:

The review highlights the need for a dynamic and responsive drug delivery system to better match the physiological regulation of thyroid hormones, addressing the limitations of current therapies.

Limitations:

• Current dosing strategies do not account for individual variations in absorption and metabolism, leading to ineffective treatment.
• Fixed dosing approaches are simplistic and often ineffective for diverse patient populations, resulting in significant variability in patient outcomes.

Conclusion:

The development of an Intelligent Medicine Bot could significantly improve the management of thyroid hormone replacement therapy by providing a more responsive and individualized treatment approach.